Researchers at Amsterdam UMC have reported the first documented case of CRISPR gene editing successfully removing HIV from infected cells in a living human patient. The result, published in Nature Medicine, is preliminary — a single patient, early-phase trial with a follow-up period of months rather than years — but it has been received as a significant proof of concept by the scientific community.

The patient, a man in his fifties who had been living with HIV for over two decades, received an intravenous infusion of gene-editing molecules designed to target and cut out proviral DNA — the integrated form of HIV that hides inside host cells and evades conventional antiretroviral therapy. Twelve weeks after the infusion, researchers detected no HIV DNA in the vast majority of sampled cells.

The technical challenge CRISPR faces with HIV is precisely what makes it interesting. Antiretroviral drugs suppress the virus but cannot eliminate it; the moment treatment is interrupted, the virus rebounds from a reservoir of latently infected cells. CRISPR's promise is that it could surgically excise those reservoirs rather than merely suppress them.

There are significant caveats. The patient remains on antiretroviral therapy. Researchers have not yet attempted a structured treatment interruption to test whether the editing is sufficient to prevent viral rebound. Delivery — getting the editing machinery into every relevant cell in the body — remains a major unsolved problem. Off-target edits, where CRISPR cuts DNA at unintended locations, were detected at low levels and their long-term significance is unknown.

Previous attempts to cure HIV through other means, including bone marrow transplants with donor cells naturally resistant to the virus, have succeeded in a small number of patients but involve procedures too risky and complex for broad use. CRISPR, if it can be made to work reliably, would be manufacturable and scalable in a way bone marrow transplants are not.

The Amsterdam team expects to expand the trial to a small cohort of additional patients within the next year. Full publication of the methodology has allowed other research groups to begin parallel work. A realistic timeline to a potential therapy, if all stages of development go well, would be somewhere between eight and fifteen years.

#medicine

CRISPR Gene Editing Clears HIV From Cells in Human Trial — A First